Is this email not displaying correctly? View it in your browser.
Newswise - News for Journalists
Newswise Special Wire
Tuesday, October 1, 2019

Public edition |

Newswise Cancer Research Wire for 01-Oct-2019

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led b...

– University of Texas M. D. Anderson Cancer Center

New England Journal of Medicine

Embargo expired on 30-Sep-2019 at 02:30 ET

Adding Targeted Therapy Drug to Hormone Therapy Helps Women with Aggressive Breast Cancer Live Longer

A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy has been shown to significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast c...

– University of California, Los Angeles (UCLA), Health Sciences

2019 European Society for Medical Oncology (ESMO) Congress

Embargo expired on 29-Sep-2019 at 10:30 ET

New blood test capable of detecting multiple types of cancer

A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows.

– Dana-Farber Cancer Institute

ESMO Congress 2019

Embargo expired on 28-Sep-2019 at 02:30 ET

PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival (PFS) for pa...

– University of Texas M. D. Anderson Cancer Center

New England Journal of Medicine

Embargo expired on 28-Sep-2019 at 10:30 ET

Study Shows Nearly Half of Cancer Patients Who Enter a Comprehensive Tobacco Treatment Program Quit Smoking

In the largest smoking cessation study of cancer patients to date, researchers from The University of Texas MD Anderson Cancer Center found that comprehensive tobacco treatment can help cancer patients successfully quit and abstain from smoking.

– University of Texas M. D. Anderson Cancer Center

JAMA Network Open

Embargo expired on 27-Sep-2019 at 11:00 ET

Common TB Vaccine May Lower Lung Cancer Risk

A common tuberculosis (TB) vaccine could decrease the risk of lung cancer if administered during early childhood, according to a study published Sept. 25 in JAMA Network Online.

– Uniformed Services University of the Health Sciences (USU)


Embargo expired on 25-Sep-2019 at 11:00 ET

Investigational Drug with Immunotherapy May Provide New Therapeutic Opportunity for Patients Previously Treated for Kidney and Lung Cancer

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer. Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase IB study

– University of Texas M. D. Anderson Cancer Center

Lancet Oncology

Embargo expired on 25-Sep-2019 at 18:30 ET

Bioengineer Building Brighter Way for Capturing Cancer During Surgery

University of Texas at Dallas researchers have demonstrated that imaging technology used to map the universe shows promise for more accurately and quickly identifying cancer cells in the operating room.

– University of Texas at Dallas

Cancers; RP190588; CA176684; CA156775; CA204254

Latest Global Immuno-Oncology Landscape Report from the Cancer Research Institute Published in Nature Reviews Drug Discovery

Cancer Research Institute analysis of the global immuno-oncology landscape shows dramatic two-year growth in therapeutic targets and I-O drugs in clinical development

– Cancer Research Institute

Yu et al. “Immuno-oncology drug development goes global.” Nat Rev. Drug Discov. 27 Sep 2019.

Researchers show genetic mutations in advanced lung cancer may predict improved outcomes

According to new findings by Yale Cancer Center scientists, higher levels of genetic mutations in a tumor biopsy are linked to improved clinical outcomes in patients using pembrolizumab (Keytruda) to treat non-small cell lung cancer (NSCLC).

– Yale Cancer Center

ESMO 2019

Long-term hormone therapy increases mortality risk for men with low PSA levels after prostate surgery

A secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer finds long-term hormone therapy does more harm than good for many men and calls for rethinking treatment guidelines based on a pa...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2019

Trial reports randomized evidence high-dose radiation is effective for men whose prostate cancer has spread

A randomized clinical trial of targeted, high-dose radiation for men with oligometastatic prostate cancer has shown the treatment to be an effective and safe option for patients who wish to delay hormone-suppression therapy. The phase II trial found ...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2019

Noninvasive radiation treatment offers long-term benefits to patients with high-risk heart arrhythmias

Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically reduce episodes of rapid, abnormal heartbeats for more than two years, offering hope to patients who have exhausted other treatment options. Findings wer...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2019

Women’s health clinics closures associated with higher cervical cancer mortality and lower screening rates

Following the closure of nearly 100 women’s health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose. Findings f...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2019

Artificial Intelligence accurately predicts radiation treatment side effects for patients with head and neck cancers

For the first time, a sophisticated computer model has been shown to accurately predict two of the most challenging side effects associated with radiation therapy for head and neck cancer. This precision oncology approach has the potential to better ...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2019

Adding radiation after immunotherapy improves progression-free survival for some patients with metastatic lung cancer

Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates the immune system in some patients with metastatic non-small-cell lung cancer (NSCLC), increasing progression-free survival (PFS). Fi...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2019

Women equally satisfied with cosmetic results of both partial and whole breast radiation therapy after lumpectomy

Whole breast radiation and partial breast radiation following a lumpectomy yield similar cosmetic outcomes for women diagnosed with early stages of cancer who wish to preserve their breasts. Findings of the new analysis from a phase III clinical tria...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2019

PACIFIC survival rates explained: Lung cancer spread reduced, new distant growth most often in the brain

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distan...

– American Society for Radiation Oncology (ASTRO)

ASTRO Annual Meeting, Sep-2019

Johns Hopkins researchers identify one driver of melanoma spread

Using a small noncoding RNA, microRNA 211, and tools that track the stability and decay of the protein-coding and noncoding RNAs in lab-grown melanoma cells, a team led by a Johns Hopkins Kimmel Cancer Center researcher identified highly unstable RNA...

– Johns Hopkins Medicine

RNA Biology; R21CA202197, NCI 5P30CA030199, P30 CA006973

Resistance to immune checkpoint blocker drug linked to metabolic imbalance

A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists from Dana-Farber Cancer Institute.

– Dana-Farber Cancer Institute

Nature Communications, Sept. 25, 2019; SU2C-AACR-DT22-17; U01CA217848

Scientists tackle potential drug resistance by using new single-cell genetic method

Using a new technique that can identify genetic profiles of individual cells, University of Notre Dame researchers modeled a breast cancer tumor’s potential resistance to a drug, and then identified a drug combination that reversed that resistance....

– University of Notre Dame

Nature Communications

Oncologists Respond Swiftly to FDA Safety Alerts, Penn Study Finds

Within six months of the FDA's move to restrict the label of two immunotherapies, usage of those therapies among oncologists dropped by about 50 percent, according to a new study from researchers in the Abramson Cancer Center at the University of Pen...

– Perelman School of Medicine at the University of Pennsylvania


Cancer Experts and Features



– Mayo Clinic

دراسة تكتشف طريقة جديدة لجعل العلاج الكيميائي أكثر فعالية في مقاومة سرطان البنكرياس


– Mayo Clinic

Clinical Cancer Research

Estudo descobre nova forma de aumentar a eficácia da quimioterapia contra o câncer de pâncreas

O adenocarcinoma pancreático (ACDP) é um carcinoma letal geralmente resistente à quimioterapia. Os pesquisadores têm buscado formas de aumentar a sensibilidade dos tumores aos medicamentos de combate ao câncer.

– Mayo Clinic

Clinical Cancer Research

Une étude révèle un nouveau moyen de rendre la chimiothérapie plus efficace contre le cancer du pancréas

L'adénocarcinome du pancréas (PDAC) est une tumeur maligne mortelle qui résiste le plus souvent à la chimiothérapie. Les chercheurs ont cherché des moyens d'accroître la sensibilité des tumeurs aux médicaments anticancéreux.

– Mayo Clinic

Clinical Cancer Research

Studie findet neuen Weg, um Chemotherapie gegen Bauchspeicheldrüsenkrebs wirksamer zu machen

Das Pankreasadenokarzinom (PDAC) ist ein letales Malignom, das am häufigsten gegen eine Chemotherapie resistent ist. Forscher haben nach Möglichkeiten gesucht, die Anfälligkeit der Tumore für krebsbekämpfende Medikamente zu erhöhen.

– Mayo Clinic

Clinical Cancer Research

New Mayo Clinic Press book offers help, hope to fibromyalgia patients

Fibromyalgia, a disorder that causes pain, fatigue, chronic headaches and a host of other symptoms, is often misunderstood by patients, families and health care providers. A new book from Mayo Clinic Press aims to change that.

– Mayo Clinic

Estudio descubre nueva manera de hacer más eficaz a la quimioterapia contra el cáncer pancreático

El adenocarcinoma pancreático (PDAC, por sus siglas en inglés) es un cáncer mortal y muy a menudo refractario a la quimioterapia. Por ello, los investigadores buscan maneras de mejorar la sensibilidad tumoral a los fármacos contra el cáncer.

– Mayo Clinic

Mayo Clinic的研究人员将在ASTRO年会上发布研究结果

Mayo Clinic的医生将在美国放射治疗及肿瘤学会年会(9月15日至18日在芝加哥举行)上发表研究结果。

– Mayo Clinic

Detecting Neurocognitive Change in Pediatric Cancer Patients

Although cure rates for children with cancer are increasing, cancer treatments can cause permanent deterioration of brain functions leading to impairments in attention, concentration, memory and learning. With the aid of a $3.4 million NIH grant, a R...

– Rutgers Cancer Institute of New Jersey


The Medical Minute: Breast density — Separating myth from fact

Mammograms remain the gold standard for detecting breast cancer in its earliest stages, potentially saving lives. So, why do some women receive a letter after a negative mammogram – meaning there’s no sign of cancer – asking them to consider ad...

– Penn State Health

Children’s of Alabama Doctor Using Herpes Virus To Fight Brian Tumors

Children’s of Alabama is home to one of the most exciting studies underway in pediatric cancer: evaluating the use of a cold sore virus to treat children with progressive malignant brain tumors.

– Children's of Alabama

Lumpectomy for Breast Cancer with Attention to Cosmetic Results

As more women live with breast cancer, minimization of significant deformity in the breast after breast preservation is increasingly gaining attention. A Rutgers Cancer Institute of New Jersey surgical oncologist shares some insight.

Expert Available

– Rutgers Cancer Institute of New Jersey

Risk Factors and Screening for Breast Cancer

M. Michele Blackwood, MD, FACS, chief of breast surgery at Rutgers Cancer Institute of New Jersey and medical director/Northern regional director of breast services at RWJBarnabas Health, shares expertise on breast cancer risk factors and screening. ...

– Rutgers Cancer Institute of New Jersey

Cancer Announcements

Biologist Carlos Carmona-Fontaine Receives NIH Director's New Innovator Award

Carlos Carmona-Fontaine, assistant professor of biology and a member of the Center for Genomics and Systems Biology at New York University, has been selected by the National Institutes of Health (NIH) for its highly competitive New Innovator Award. ...

– New York University

World’s Largest Road Hockey Fundraiser Raises $3.1 Million for Cancer Research

More than 1,900 participants, making up 167 teams, faced off today at Woodbine Racetrack in Toronto and raised a record-breaking $3.1 million as part of the 9th annual Scotiabank Road Hockey to Conquer Cancer. This brings the annual event’s nine-ye...

– University Health Network (UHN)

Cancer Research Institute Announces 2019 Recipients of Its Top Scientific and Philanthropic Awards Honoring Discovery, Service in AdvancingCancer Immunology and Immunotherapy Research

The Cancer Research Institute (CRI), a nonprofit organization dedicated to advancing the discovery and development of powerful immunotherapies for all forms of cancer, has announced the 2019 recipients of its highest scientific and philanthropic awar...

– Cancer Research Institute

AIDS and Cancer Specimen Resource Renewed with $22 Million Grant

The ACSR has been renewed for five years with the George Washington University serving as the prime site.

– George Washington University

Wayne State, Karmanos receive $3.1 million NIH grant to improve quality of life for African American cancer survivors

Funding from the National Cancer Institute will help a team of researchers from Wayne State University and the Barbara Ann Karmanos Cancer Institute to investigate the combined role that community, interpersonal and individual influences have on the ...

– Wayne State University Division of Research

National Cancer Institute - 232514-01

Cancer Research

Vaccine to Block Digestive Hormone May Slow Growth of Pancreatic Cancer

– American Physiological Society (APS)

American Journal of Physiology - Gastrointestinal and Liver Physiology

Embargo expired on 01-Oct-2019 at 08:00 ET

Childhood Cancer Treatment Can Alter Leydig Cell Function

– St. Jude Children's Research Hospital

Journal of Clinical Oncology. Sep-2019

Breast Cancer in San Francisco: Disentangling Disparities at the Neighborhood Level

– UCSF Helen Diller Family Comprehensive Cancer Center

(Cancer Epidemiology, Biomarkers & Prevention)10.1158/1055-9965.EPI-19-0799





 Edit My Preferences
 Contact Us
 Newswise Home
 Newswise Contact Directory
 Expert Queries
 Presspass Application

More News from:

 George Washington University

 Wayne State University Division of Research

 University of Notre Dame

 University of Texas M. D. Anderson Cancer Center

 Penn State Health

 University of California, Los Angeles (UCLA), Health Sciences

 American Physiological Society (APS)

Subscribe / Unsubscribe
Edit my preferences

© 2019 Newswise, Inc. All Rights Reserved.

265 Turkey Sag Trail Suite 102, #110 Palmyra VA 22963 | 434-296-9417

 Contact Us